Abstract
Primary results from the phase 3 RATIONALE-307 study (NCT03594747) showed significantly prolonged PFS, higher ORR, and a tolerable safety profile for TIS + chemo as first-line treatment for sq NSCLC. We report results from a post-hoc safety analysis of TIS + chemo vs chemo alone.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
